头颈部特应性皮炎的诊疗研究进展

doi:10.35541/cjd.20230562

Abstract

Abstract: 【Abstract】 Atopic dermatitis is a chronic relapsing inflammatory dermatosis with heterogeneity at different body sites. Atopic dermatitis of the head and neck has received increasing attention as a special-site subtype. This review summarizes the research progress in atopic dermatitis of the head and neck from the aspects of etiology and pathogenesis, clinical manifestations, auxiliary examinations, diagnosis and differential diagnosis, as well as treatment and management, aiming to provide new ideas for its clinical diagnosis and treatment.

Key words: Dermatitis, atopic, Head-and-neck dermatitis, Malassezia, Dupilumab, Treatment

Li Fang, Lin Ying. Diagnosis and treatment of atopic dermatitis of the head and neck[J]. Chinese Journal of Dermatology,2024,e20230562. doi:10.35541/cjd.20230562

References ［40］

［1］	Bax CE, Khurana MC, Treat JR, et al. New⁃onset head and neck dermatitis in adolescent patients after dupilumab therapy for atopic dermatitis［J］. Pediatr Dermatol, 2021,38（2）:390⁃394. doi: 10.1111/pde.14499.
［2］	Guglielmo A, Sechi A, Patrizi A, et al. Head and neck dermatitis, a subtype of atopic dermatitis induced by Malassezia spp: clinical aspects and treatment outcomes in adolescent and adult patients［J］. Pediatr Dermatol, 2021,38（1）:109⁃114. doi: 10.1111/ pde.14437.
［3］	Chu H, Kim SM, Zhang K, et al. Head and neck dermatitis is exacerbated by Malassezia furfur colonization, skin barrier disruption, and immune dysregulation［J］. Front Immunol, 2023,14:1114321. doi: 10.3389/fimmu.2023.1114321.
［4］	Dirschka T, Szliska C, Jackowski J, et al. Impaired skin barrier and atopic diathesis in perioral dermatitis［J］. J Dtsch Dermatol Ges, 2003,1（3）:199⁃203. doi: 10.1046/j.1610⁃0387.2003. 02039.x.
［5］	林洁, 杨连娟, 杨名珍. 头颈部特应性皮炎患者面部马拉色菌的菌种分布［J］. 中国真菌学杂志, 2021,16（3）:161⁃165. doi: 10.3969/j.issn.1673⁃3827.2021.03.004.
［6］	Zheng Y, Wang Q, Ma L, et al. Alterations in the skin microbiome are associated with disease severity and treatment in the perioral zone of the skin of infants with atopic dermatitis［J］. Eur J Clin Microbiol Infect Dis, 2019,38（9）:1677⁃1685. doi: 10.1007/s10096⁃019⁃03598⁃9.
［7］	Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: a report of two cases［J］. J Eur Acad Dermatol Venereol, 2023,37（3）:e300⁃e302. doi: 10.1111/jdv.18743.
［8］	Muzumdar S, Skudalski L, Sharp K, et al. Dupilumab facial redness/dupilumab facial dermatitis: a guide for clinicians［J］. Am J Clin Dermatol, 2022,23（1）:61⁃67. doi: 10.1007/s40257⁃021⁃00646⁃z.
［9］	Mayser P, Kupfer J, Nemetz D, et al. Treatment of head and neck dermatitis with ciclopiroxolamine cream⁃⁃results of a double⁃blind, placebo⁃controlled study［J］. Skin Pharmacol Physiol, 2006,19（3）:153⁃158. doi: 10.1159/000092596.
［10］	Patruno C, Ferrillo M, Fabbrocini G, et al. A case of dirty neck in severe and diffuse atopic dermatitis successfully treated with dupilumab［J］. Dermatol Ther, 2021,34（1）:e14556. doi: 10. 1111/dth.14556.
［11］	Woo YR, Cho M, Han Y, et al. Characterization of distinct microbiota associated with scalp dermatitis in patients with atopic dermatitis［J］. J Clin Med, 2022,11（6）. doi: 10.3390/jcm11061735.
［12］	de Wijs L, Nguyen NT, Kunkeler A, et al. Clinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case series［J］. Br J Dermatol, 2020,183（4）:745⁃749. doi: 10.1111/bjd.18730.
［13］	Kozera E, Stewart T, Gill K, et al. Dupilumab⁃associated head and neck dermatitis is associated with elevated pretreatment serum Malassezia⁃specific IgE: a multicentre, prospective cohort study［J］. Br J Dermatol, 2022,186（6）:1050⁃1052. doi: 10.1111/bjd.21019.
［14］	Kozera E, Flora A, Stewart T, et al. Dupilumab⁃associated head and neck dermatitis resolves temporarily with itraconazole therapy and rapidly with transition to upadacitinib, with Malassezia⁃specific immunoglobulin E levels mirroring clinical response［J］. J Am Acad Dermatol, 2023,88（1）:255⁃257. doi: 10.1016/j.jaad.2022.05.021.
［15］	Liane JG, Morgado⁃Carrasco D. Dupilumab⁃associated facial erythema successfully treated with oral ivermectin［J］. Dermatol Pract Concept, 2022,12（4）:e2022184. doi: 10.5826/dpc.1204a184.
［16］	Navarro⁃Triviño FJ, Vega⁃Castillo JJ, Llamas⁃Molina JM, et al. Refractory head and neck atopic dermatitis pattern treated with dupilumab: allergic contact dermatitis caused by decyl glucoside. Should surfactants be patched?［J］. Australas J Dermatol, 2021,62（4）:509⁃511. doi: 10.1111/ajd.13678.
［17］	Napolitano M, Fabbrocini G, Patruno C. Allergic contact dermatitis to compositae: a possible cause of dupilumab⁃associated facial and neck dermatitis in atopic dermatitis patients?［J］. Contact Dermatitis, 2021,85（4）:473⁃474. doi: 10. 1111/cod.13898.
［18］	Gao H, Zhang Z, Ma L, et al. Photosensitivity is an important cause of refractory facial erythema in atopic dermatitis: a retrospective study of 82 Chinese patients［J］. Photodermatol Photoimmunol Photomed, 2023,39（4）:318⁃324. doi: 10.1111/phpp.12836.
［19］	中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南（2020版）［J］. 中华皮肤科杂志, 2020,53（2）:81⁃88. doi: 10.35541/cjd.20191000.
［20］	中华医学会皮肤性病学分会免疫学组. 特应性皮炎的全程管理共识［J］. 中华皮肤科杂志, 2023,56（1）:5⁃15. doi: 10.35541/cjd.20220618.
［21］	Kachiu C, Dennis W, Jaimee H, et al. Novel use of a cooling pillow for treatment of severe head and neck atopic dermatitis［J］.Retour au numéro, 2013,68（4）:AB77. doi: https://doi.org/10.1016/ j.jaad.2012.12.319
［22］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组, 中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识［J］. 中华皮肤科杂志, 2022,55（4）:281⁃288. doi: 10.35541/cjd.20210833.
［23］	Wollenberg A, Kinberger M, Arents B, et al. European guideline （EuroGuiDerm） on atopic eczema ⁃ partⅡ: non⁃systemic treatments and treatment recommendations for special AE patient populations［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:1904⁃1926. doi: 10.1111/jdv.18429.
［24］	中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中华医学会皮肤性病学分会儿童学组. 特应性皮炎湿包疗法临床应用专家共识［J］. 中华皮肤科杂志, 2022,55（4）:289⁃294. doi: 10.35541/cjd.20210823.
［25］	Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies［J］. J Am Acad Dermatol, 2023,89（1）:e1⁃e20. doi: 10.1016/j.jaad.2022.12.029.
［26］	Tsai YC, Tsai TF. Facial erythema during dupilumab treatment for atopic dermatitis successfully remedied with topical crisaborole ointment: a case report［J］. Dermatol Ther, 2022,35（11）:e15843. doi: 10.1111/dth.15843.
［27］	Miyagaki T, Okano T, Nakajima K, et al. A case of facial redness in atopic dermatitis occurring during dupilumab treatment successfully treated with topical delgocitinib ointment［J］. Dermatol Ther, 2021,34（2）:e14888. doi: 10.1111/dth.14888.
［28］	Simpson EL, Paller AS, Siegfried EC, et al. Dupilumab demonstrates rapid and consistent improvement in extent and signs of atopic dermatitis across all anatomical regions in pediatric patients 6 years of age and older［J］. Dermatol Ther （Heidelb）, 2021,11（5）:1643⁃1656. doi: 10.1007/s13555⁃021⁃00568⁃y.
［29］	Ahn J, Lee DH, Na CH, et al. Facial erythema in patients with atopic dermatitis treated with dupilumab ⁃ a descriptive study of morphology and aetiology［J］. J Eur Acad Dermatol Venereol, 2022,36（11）:2140⁃2152. doi: 10.1111/jdv.18327.
［30］	中华医学会皮肤性病学分会特应性皮炎研究中心, 中华医学会皮肤性病学分会儿童学组. 度普利尤单抗治疗特应性皮炎专家共识［J］. 中华皮肤科杂志, 2022,55（6）:465⁃470. doi: 10. 35541/cjd.20210885.
［31］	Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five phaseⅢ clinical trials［J］. Eur J Dermatol, 2022,32（4）:522⁃529. doi: 10.1684/ejd.2022.4280.
［32］	Alexis A, de Bruin⁃Weller M, Weidinger S, et al. Rapidity of improvement in signs/symptoms of moderate⁃to⁃severe atopic dermatitis by body region with abrocitinib in the phase 3 JADE COMPARE Study［J］. Dermatol Ther （Heidelb）, 2022,12（3）:771⁃785. doi: 10.1007/s13555⁃022⁃00694⁃1.
［33］	陈教全, 余南极, 高爱莉, 等. 乌帕替尼治疗度普利尤单抗抵抗的面颈部特应性皮炎患者1例［J/OL］. 中国皮肤性病学杂志: 1⁃4［2023⁃12⁃28］. doi: 10.13735/j.cjdv.1001⁃7089.2023 01016.
［34］	Jang YK, Kim DH, Yoon MS, et al. Development of desquamation with Staphylococcus aureus colonization in patients with atopic dermatitis under treatment with upadacitinib［J］. Clin Exp Dermatol, 2023,48（3）:240⁃242. doi: 10.1093/ced/llac068.
［35］	Samia AM, Cuervo⁃Pardo L, Montanez⁃Wiscovich ME, et al. Dupilumab⁃associated head and neck dermatitis with ocular involvement in a ten⁃year⁃old with atopic dermatitis: a case report and review of the literature［J］. Cureus, 2022,14（7）:e27170. doi: 10.7759/cureus.27170.
［36］	Ordóñez⁃Rubiano MF, Casas M, Balaguera⁃Orjuela V. Dupilumab facial redness: clinical characteristics and proposed treatment in a cohort［J］. Dermatol Ther, 2021,34（6）:e15140. doi: 10.1111/dth.15140.
［37］	Chen M, Gao K, Ali K, et al. Case report: dupilumab leads to an increased chance of head and neck Staphylococcus aureus infection in atopic dermatitis patients［J］. Front Med （Lausanne）, 2023,10:1027589. doi: 10.3389/fmed.2023.1027589.
［38］	Murase JE, Chovatiya R, Strowd L, et al. 381 improved and cleared facial and hand dermatitis with lebrikizumab in patients with moderate⁃to⁃severe atopic dermatitis［J］. British Journal of Dermatology, 2023,188（Supplement_3）:ljad162.009. doi: 10.1093/ bjd/ljad162.009.
［39］	Labib A, Ju T, Yosipovitch G. Managing atopic dermatitis with lebrikizumab ⁃ the evidence to date［J］. Clin Cosmet Investig Dermatol, 2022,15:1065⁃1072. doi: 10.2147/CCID.S295672.
［40］	Head, neck dermatitis improved with rocatinlimab \| Mount Sinai ⁃ New York［EB/OL］. Mount Sinai Health System. （2023⁃07⁃18）. https://www.mountsinai.org/about/newsroom/2022/head⁃neck⁃dermatitis⁃improved⁃with⁃rocatinlimab.

[1]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[2]	Huang Hejin, Li Xinya, He Ziqing, Xi Wenwen, Tang Yujun, Zhang Jianfei, Xiao Xia, Jiang Bin, Yang Feng. Postoperative complications in 3 000 patients with axillary osmidrosis after minimally invasive rotary cutting surgery: a retrospective study [J]. Chinese Journal of Dermatology, 2025, 0(5): 20230291-e0230291.
[3]	Bao Shijie, Han Mei, Zhou Xiaoyong. Analysis of factors influencing the efficacy of etanercept in the treatment of toxic epidermal necrolysis based on literature review [J]. Chinese Journal of Dermatology, 2025, 58(4): 352-355.
[4]	Mu Kui, Guo Hui, Wen Haiquan, Long Hai, Liu Yu, Luo Shuaihantian, Huang Xin, Zhou Xingyu, Xiao Rong, Li Yaping. Efficacy and safety analysis of combined telitacicept in 25 patients with systemic lupus erythematosus based on standard therapy [J]. Chinese Journal of Dermatology, 2025, 58(4): 322-327.
[5]	Chinese Society of Dermatology, China Dermatologist Association, Dermatology Branch of China International Exchange and Promotive Association for Medical and Health Care, Rare Skin Diseases Committee, China Alliance for Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases. Expert consensus on the diagnosis and treatment of paraneoplastic pemphigus in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 289-296.
[6]	Wang Caixia, Xu Fan, Shi Jing, Zhu Hailian, Lu Guiling, Wang Hongmei. Efficacy and safety of omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220929-e0220929.
[7]	Guo Weinan, Wang Junxia, Chen Hui, Hao Junfeng, Li Bing, Wei Jingyi, Zhao Tao. Clinical efficacy of autologous adipose-derived stem cell gel grafting in the treatment of depressed acne scars [J]. Chinese Journal of Dermatology, 2025, 58(2): 167-169.
[8]	Zhou Miaoni, Sheng Anqi, Fu Lifang, Jin Rong, Xu Wen, Wei Xiaodong, Xu Ai′e . Efficacy and safety of tea polyphenol antioxidant gel combined with narrow-band ultraviolet B in the treatment of vitiligo: a single-center randomized controlled trial [J]. Chinese Journal of Dermatology, 2025, 0(2): 20240421-e20240421.
[9]	Jin Lan, Qiu Yun, Wang Weijia, Kang Xiaojing, Ding Yuan. Clinical efficacy and safety of biological agents in the treatment of moderate-to-severe psoriasis in 124 elderly patients: a retrospective analysis [J]. Chinese Journal of Dermatology, 2025, 58(1): 47-52.
[10]	Yang Zijing, Chen Lihong, Ruan Yeping, Wen Wanting, Zhang Jiayi, Wang Hailun, Pan Meng, Zhao Xiaoqing. Efficacy and safety of dupilumab in the treatment of atopic dermatitis in the elderly [J]. Chinese Journal of Dermatology, 2025, 58(1): 65-69.
[11]	Xia Manqi, Shao Lei, Huang Qiongxiao, Tian Xin, Liang Yimin, Huang Ting, Liang Jingyao, Liu Yumei. Efficacy and safety of dupilumab in the treatment of prurigo nodularis: a multicenter retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(8): 679-684.
[12]	Song Yuqing, Yang Nan, Liu Linlin, Feng Ziyi, Han Shixin, Zhou Meijuan. Dermabrasion for the treatment of familial benign chronic pemphigus: a clinical observation of 6 cases [J]. Chinese Journal of Dermatology, 2024, 57(8): 743-746.
[13]	Hu Qingjie, Xu Kang, Zhu Hong, Yao Xu. Drug survival rate and safety of dupilumab in the treatment of atopic dermatitis in elderly patients: a retrospective cohort analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 632-636.
[14]	Diao Ping, Han Chenglong, Liu Lian, Zhou Hui, Li Erlong, Jiang Xian. Efficacy and influencing factors of hematoporphyrin monomethyl ether-mediated photodynamic therapy in the treatment of adult patients with port-wine stains: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(7): 595-600.
[15]	Zhang Ting, Liu Lian, Chen Haotian, Wei Danfeng, Liu Xu, Diao Ping, Liu Qingfeng, Jiang Xian. Efficacy of 595-nm pulsed dye laser in the treatment of port‐wine stains in 155 infants and toddlers: a retrospective analysis [J]. Chinese Journal of Dermatology, 2024, 57(7): 610-615.

Diagnosis and treatment of atopic dermatitis of the head and neck

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［40］

Related Articles 15

Metrics

Comments

Recommended 10